ProCE Banner Activity

Phase I/II Trial of Triplet Combination of Gilteritinib + Azacitidine/Venetoclax in Patients With FLT3-Mutated AML: Updated Results

Slideset Download
Conference Coverage

Updated results from a phase I/II trial of gilteritinib in combination with azacitidine/venetoclax show high CR rates and MRD negativity in frontline and relapsed/refractory FLT3-mutated AML.

Released: December 15, 2022

Expiration: December 14, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen